Breaking Update
Israeli Company Joins U.S. Trial on Ulcerative Colitis Treatment
Israeli firm Evinature's CurQD will be part of a U.S. DoD trial for ulcerative colitis, involving Mount Sinai and University of Chicago.
Jerusalem, 19 March, 2026 (TPS-IL) — Israeli nutraceutical company Evinature will provide its proprietary CurQD formulation for a U.S. Department of Defense-funded clinical trial investigating a combination approach for ulcerative colitis. The study, led by Mount Sinai Hospital and the University of Chicago Medicine, will also involve Sheba Medical Center in Israel.
CurQD, which combines curcumin and QingDai, will be tested alongside the biologic vedolizumab to explore whether the plant-based supplement can enhance treatment outcomes. The trial received an initial $800,000 planning grant, with potential funding up to $11 million.
Researchers hope the study will improve response rates and offer patients a complementary, non-pharmaceutical option for managing this chronic gut condition.
